Inozyme Pharma Reports Second Quarter 2022 Financial Results

15.08.2022 - - Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - ...

Related Keywords

United States , Boston , Massachusetts , Axel Bolte , Inozyme Pharma , Stefan Riley , Matt Pera , Kurt Gunter , Joseph Schlessinger , Demetrios Braddock , Yale University , Inozyme Pharma Inc , Beginngs Consortium , Nasdaq , Exchange Commission , Development Rd Expenses , Rady Children Institute For Genomic Medicine , European Calcified Tissue Society Congress , Data Safety Monitoring Board , Natural History , Clinical Trial , Publications Peer Reviewed , Experimental Dermatology , Rady Children , Genomic Medicine , Whole Genome Sequencing , Debt Facility , Financial Guidance , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Consolidated Statements , Months Ended June ,